{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.80","value":"2.1"},{"groupId":"OG001","spread":"0.78","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"836"},{"groupId":"OG001","value":"769"}],"units":"Participants"}],"description":"Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.","dispersionType":"Standard Error","groups":[{"description":"Participants received capecitabine 1250 (mg/m \\^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).","id":"OG000","title":"Capecitabine"},{"description":"Participants received leucovorin 20 mg/m \\^ 2 followed by 5-fluorouracil at 425 mg/m \\^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).","id":"OG001","title":"5-Fluorouracil + Leucovorin"}],"paramType":"MEAN","populationDescription":"The safety population included all participants who received at least one dose of capecitabine, 5-fluorouracil, or leucovorin and had at least one post baseline safety assessment (adverse events, laboratory test results, or vital signs).","reportingStatus":"POSTED","timeFrame":"Baseline (Days -7 to 1) and at Week 25","title":"Mean Change From Baseline in Global Health Status at Week 25","type":"SECONDARY","unitOfMeasure":"Score on a scale"}